Dear Colleagues,
As we move into summer, our community remains active on multiple scientific fronts. This newsletter brings updates on upcoming congresses, a reminder on the working group elections, and a selection of recommended reading from recent months.
ESC Congress 2026 in Munich: Register and enjoy
ESC Congress 2026 will take place in Munich, Germany, from 28 to 31 August 2026, at Messe München. We strongly encourage working group members to attend and contribute to a visible and active presence of the atherosclerosis and vascular biology community at this flagship event. As every year, two Young Investigator Awards will be awarded to presenters of outstanding abstracts submitted by early-career scientists. Could a member of the ESC Working Group on Atherosclerosis & Vascular Biology be a winner this year?
Working Group elections - your vote matters
Elections for Nucleus Member, Secretary, and Chair-Elect positions are approaching. All working group members are warmly invited to review the profiles of the candidates and cast their vote. A dedicated email with full instructions and voting details will reach you before the opening of the online voting period (10–24 June). Please look out for it and make your voice heard - active participation from our community is what shapes the future direction of our working group. Find out more.
Best Translational Paper Call - reminder
As announced in our previous newsletter, the our working group is running two annual calls for the Best Translational Paper. The deadline is 31 July 2026. Eligible investigators (first author, age < 40, paper published from August 2025 onward) are encouraged to submit their CV, a letter of application, and a copy of the published article. Submit via email (please use the subject line: Best translational paper).
Recommended reading
African representation in cardiovascular trials: Gaye B et al. examined African representation in randomized controlled trials published in leading medical and cardiovascular journals between 2019 and 2024, highlighting a persistent and striking underrepresentation with important implications for generalizability of evidence. J Am Coll Cardiol. 2026;87(15):1892–1906. DOI: 10.1016/j.jacc.2026.02.5097
Cancer and heart failure: a Scottish population perspective: Iaconelli A, Morsy MI et al. reported on the prevalence, incidence, and prognosis of concurrent cancer and heart failure in Scotland, providing large-scale epidemiological data relevant to the growing field of cardio-oncology. Eur Heart J. 2026. Epub ahead of print. DOI: 10.1093/eurheartj/ehag120.
EPA ethyl ester, cardiac metabolomics, and cardioprotection: Sebastià Alcover et al. explored the metabolomic and lipidomic cardiac signatures associated with eicosapentaenoic acid ethyl ester treatment, providing mechanistic insights into cardioprotection in the setting of myocardial infarction. Eur Heart J. 2026. Epub ahead of print. DOI: 10.1093/eurheartj/ehag187
Our mission and your voice
Our main mission remains advancing the science of atherosclerosis and vascular biology while fostering collaboration and knowledge exchange. If you have suggestions for topics, emerging research of interest, or ideas to enhance our activities, please reach out to Luca Liberale with the subject line: WG Atherosclerosis Vascular Biology.
Thank you for being an integral part of our community. We look forward to connecting with you online via X and LinkedIn (#AtheroMatters) and to seeing many of you at ESC Congress 2026 and other exciting events this year.
Pictures from participants @FCVB26
Prof. Philip Swirsky, keynote Lecturer and the two chairpersons prof. Elena Osto and Fabrizia Bonacina
Speakers and chairpersons of the session on “The exposome and cardiovascular disease”
Warm regards,
Luca, Holger, Simon & Elena
On behalf of the ESC Working Group on Atherosclerosis and Vascular Biology
